Pharvaris N.V.

Pharvaris N.V. (PHVS) priced its initial public offering on Feb 8, 2021 at $20.00 per share, above its $17.00–$19.00 range, raising $165.4M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $636.8M. Morgan Stanley was lead-left underwriter, joined by BofA Securities, Leerink Partners and Oppenheimer. Kirkland & Ellis advised the company and Sidley Austin advised the underwriters.

Pharvaris N.V. is a clinical-stage biopharmaceutical company developing therapies for rare diseases, initially angioedema and other bradykinin-mediated conditions. Its first molecule, PHA121, is an oral small molecule bradykinin B2-receptor antagonist for hereditary angioedema, intended as an alternative to injectable standard treatments.

Status

IPO

Ticker

PHVS

Exchange

Nasdaq Global Select

Priced

Feb 8, 2021

IPO price

$20.00

Price range

$17.00–$19.00

Raised

$165.4M

Market cap at IPO price

$636.8M

First filed

Jan 15, 2021

Underwriters

Morgan Stanley, BofA Securities, Leerink Partners and Oppenheimer

Company counsel

Kirkland & Ellis

Underwriters' counsel

Sidley Austin

Sector

Biotech & pharma

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.